Warren et al., 2003 - Google Patents
The BMP antagonist noggin regulates cranial suture fusionWarren et al., 2003
- Document ID
- 4046127166505430720
- Author
- Warren S
- Brunet L
- Harland R
- Economides A
- Longaker M
- Publication year
- Publication venue
- Nature
External Links
Snippet
During skull development, the cranial connective tissue framework undergoes intramembranous ossification to form skull bones (calvaria). As the calvarial bones advance to envelop the brain, fibrous sutures form between the calvarial plates. Expansion of the …
- 102000008872 noggin protein 0 title abstract description 100
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Warren et al. | The BMP antagonist noggin regulates cranial suture fusion | |
| Sun et al. | Functions of FGF signalling from the apical ectodermal ridge in limb development | |
| Li et al. | Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation | |
| Dr. Ting et al. | Human NELL‐1 expressed in unilateral coronal synostosis | |
| Wang et al. | Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin | |
| Harada et al. | FGF9 monomer–dimer equilibrium regulates extracellular matrix affinity and tissue diffusion | |
| Wang et al. | Type IV collagens regulate BMP signalling in Drosophila | |
| Zhang et al. | The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd | |
| Gong et al. | LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development | |
| Haÿ et al. | N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/β-catenin signaling, osteoblast function, and bone formation | |
| James et al. | Different roles of Runx2 during early neural crest–derived bone and tooth development | |
| Kokubu et al. | Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis | |
| Bei et al. | FGFs and BMP4 induce both Msx1-independent and Msx1-dependent signaling pathways in early tooth development | |
| Deriziotis et al. | De novo TBR1 mutations in sporadic autism disrupt protein functions | |
| Haraguchi et al. | sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss | |
| Zhao et al. | The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling | |
| Robinson et al. | Expression of a truncated FGF receptor results in defective lens development in transgenic mice | |
| Jin et al. | Prostaglandin signalling regulates ciliogenesis by modulating intraflagellar transport | |
| Yoshida et al. | The transcription factor Foxc1 is necessary for Ihh–Gli2-regulated endochondral ossification | |
| Mariner et al. | ARVCF localizes to the nucleus and adherens junction and is mutually exclusive with p120ctn in E-cadherin complexes | |
| Chanut-Delalande et al. | Development of a functional skin matrix requires deposition of collagen V heterotrimers | |
| Deglincerti et al. | Coupled local translation and degradation regulate growth cone collapse | |
| Kan et al. | SOX11 contributes to the regulation of GDF5 in joint maintenance | |
| Kahler et al. | Lymphocyte enhancer‐binding factor 1 (Lef1) inhibits terminal differentiation of osteoblasts | |
| Ihida-Stansbury et al. | Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension |